Fate Therapeutics to Present at Jefferies Cell Therapy Virtual Summit

Rhea-AI Summary

Fate Therapeutics (NASDAQ: FATE) announced its participation in the Jefferies Cell Therapy Virtual Summit on October 6, 2020, at 2:30 p.m. E.T.. The management will engage in a fireside chat to discuss advancements in their programmed cellular immunotherapies for cancer and immune disorders. A live webcast of the presentation will be accessible via the company's investor relations webpage. Fate Therapeutics is known for its innovative iPSC product platform, developing both cancer immunotherapies and treatments for immune disorders.

SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that management will participate in a fireside chat at the Jefferies Cell Therapy Virtual Summit on Tuesday, October 6, 2020 and 2:30 p.m. E.T.

A live webcast of the presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com

FAQ

When is Fate Therapeutics participating in the Jefferies Cell Therapy Virtual Summit?

Fate Therapeutics will participate in the Jefferies Cell Therapy Virtual Summit on October 6, 2020, at 2:30 p.m. E.T.

How can I watch the Fate Therapeutics presentation at the summit?

The presentation can be watched live through the investor relations section of the Fate Therapeutics website.

What is the focus of Fate Therapeutics' fireside chat at the summit?

The fireside chat will focus on their advancements in programmed cellular immunotherapies for cancer and immune disorders.

What is Fate Therapeutics known for in the biopharmaceutical industry?

Fate Therapeutics is known for its development of first-in-class cellular immunotherapies using its proprietary iPSC product platform.

What specific therapies does Fate Therapeutics offer?

Fate Therapeutics offers cancer immunotherapies, including NK cell and T-cell therapies, and immuno-regulatory products to prevent graft-versus-host disease.